Back to today’s briefing

Story perspectives

BigHat and Eli Lilly Join Forces; Earendil Nets $125M Deal

4/19/2025

25 4

Summary

Story summary

Eli Lilly is joining forces with BigHat Biosciences to revolutionize antibody therapeutics through BigHat's innovative AI-driven Milliner platform, marking a significant investment in two promising antibody programs. Meanwhile, Earendil Labs has struck a lucrative deal with Sanofi, licensing two bispecific antibodies for autoimmune diseases, netting an impressive $125 million upfront and the potential for $1.72 billion in milestone payments.

1 of 1

Story summary

Eli Lilly is joining forces with BigHat Biosciences to revolutionize antibody therapeutics through BigHat's innovative AI-driven Milliner platform, marking a significant investment in two promising antibody programs. Meanwhile, Earendil Labs has struck a lucrative deal with Sanofi, licensing two bispecific antibodies for autoimmune diseases, netting an impressive $125 million upfront and the potential for $1.72 billion in milestone payments.